financetom
Business
financetom
/
Business
/
PNB Housing reports 11.7% growth in net profit in Q2
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
PNB Housing reports 11.7% growth in net profit in Q2
Oct 27, 2022 8:37 AM

PNB Housing on Thursday, October 27, reported an 11.7 percent increase in net profit at Rs 266.6 crore for the second quarter of this fiscal over the same period last year.

The housing finance company's net interest income (NII) improved by 29 percent from corresponding quarter in the previous year and 75 percent from previous quarter. The NII stood at Rs 649 crore for the period under review.

During the September quarter, there was a net positive impact of Rs 109 crore on assigned loans, the company said in an exchange filing. The operating expenditure increased by 15 percent year-on-year (YoY) and 11 percent quarter-on-quarter (QoQ) to Rs 136 crore.

Also read: Weak earnings drag Chennai Petroleum to worst day in four months

The company's pre-provision operating profit improved by 35 percent YoY and 62 percent QoQ to Rs 584 crore. The spread on loans stood at 3.4 percent in the second quarter.

Also read: Maruti Earnings Preview: Strong volume growth to aid September quarter performance

The net interest margin stood at 4.1 percent in the second quarter compared to 3 percent in the second quarter in the previous fiscal and 2.4 percent in the previous quarter. The gross margin, net of acquisition cost, stood at 4.5 percent in the period under review against 3.3 percent in the year-ago period and 3 percent in the preceding quarter.

Shares of PNB Housing ended 4.6 percent higher at Rs 451.1 on BSE.

Catch highlights of the October 27 session

(Edited by : Shoma Bhattacharjee)

First Published:Oct 27, 2022 5:37 PM IST

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Google agrees $36 million fine for anti-competitive deals with Australia telcos
Google agrees $36 million fine for anti-competitive deals with Australia telcos
Aug 17, 2025
SYDNEY, Aug 18 (Reuters) - Google agreed on Monday to pay a A$55 million ($35.8 million) fine in Australia after the consumer watchdog found it had hurt competition by paying the country's two largest telcos to pre-install its search application on Android phones, excluding rival search engines. The fine extends a bumpy period for the Alphabet-owned internet giant in Australia,...
ConnectOne Bancorp Completes Merger With First of Long Island
ConnectOne Bancorp Completes Merger With First of Long Island
Jun 2, 2025
10:32 AM EDT, 06/02/2025 (MT Newswires) -- ConnectOne Bancorp ( CNOB ) said Monday it completed its merger with First of Long Island ( FLIC ) . The combined company is operating under the ConnectOne brand and has about $14 billion in assets. First of Long Island ( FLIC ) shareholders received 0.5175 shares of ConnectOne common stock for each...
Vera Therapeutics Says Trial of Kidney Disease Drug Achieves Primary Endpoint; Shares Jump
Vera Therapeutics Says Trial of Kidney Disease Drug Achieves Primary Endpoint; Shares Jump
Jun 2, 2025
10:31 AM EDT, 06/02/2025 (MT Newswires) -- Vera Therapeutics ( VERA ) shares climbed by nearly 60% in recent Monday trading after the biotechnology firm said a phase 3 trial of atacicept to treat immunoglobulin A nephropathy in adults achieved its primary endpoint. The primary efficacy endpoint was the change in 24-hour urine protein-to-creatinine ratio versus placebo at the 36-week...
Ascendis' New Drug Application for Investigational Drug to Treat Genetic Disorder Accepted by FDA for Priority Review
Ascendis' New Drug Application for Investigational Drug to Treat Genetic Disorder Accepted by FDA for Priority Review
Jun 2, 2025
10:34 AM EDT, 06/02/2025 (MT Newswires) -- Ascendis Pharma ( ASND ) said Monday its new drug application for the TransCon CNP candidate to treat children with achondroplasia, a genetic condition, was accepted by the US Food and Drug Administration for priority review. The FDA set a prescription drug user fee act date of November 30 to close the review...
Copyright 2023-2026 - www.financetom.com All Rights Reserved